Tuesday 20 October 2026
Export INCY’s income statement to Excel — free account
Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
116.27
3.02
+2.67%
Follow INCY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 30.67% | 30.82% | 29.87% | 30.39% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
6 | 8 | 9 | 8 | |
| 23.55% | 21.88% | 20.75% | 20.96% | ||
ROIC |
60.50% | 61.52% | 58.55% | 52.81% | |
Return on Tangible Assets |
29.73% | 30.37% | 30.35% | 31.80% | |
Average Days of Receivables |
70.57 | 71.59 | 72.73 | 67.94 | |
Free Cash Flow per Share |
9.43 | 7.13 | 6.81 | 5.99 | |
Free Cash Flow |
1,890.47 | 1,420.88 | 1,329.63 | 1,172.04 | |
Capital Expenditures |
(89.24) | (95.90) | (83.87) | (79.37) | |
| Other line items | |||||
Cash ROIC |
17.33% | 14.70% | 15.15% | 15.40% | |
Accounts Receivable Turnover |
5.91 | 5.72 | 5.48 | 5.82 | |
Accounts Payable Turnover |
1.75 | 1.90 | 1.83 | 1.94 | |
Inventory Turnover |
4.39 | 4.49 | 4.65 | 4.41 | |
Average Days of Payables |
212.72 | 206.83 | 205.92 | 184.87 | |
Days of Inventory on Hand |
95.61 | 104.60 | 99.12 | 89.73 | |
Tax Rate |
(0.18) | (0.19) | (0.23) | (0.25) | |
Research and Development Expense of Revenue |
36.96% | 39.71% | 39.88% | 39.58% | |
Selling, General and Administrative Expense of Revenue |
24.05% | 25.72% | 26.77% | 27.27% | |
Share Based Compensation of Revenue |
4.38% | 4.71% | 4.85% | 5.38% | |
Interest Coverage |
764.90 | 689.26 | 623.91 | 653.65 | |
Operating CF/Net income |
1.23 | 1.06 | 1.10 | 1.05 | |
Depreciation/Fixed assets |
0.14 | 0.13 | 0.13 | 0.12 | |
Capex/Depreciation |
(0.91) | (1.01) | (0.90) | (0.86) | |
Revenue per Share |
29.04 | 26.89 | 26.34 | 24.60 | |
Operating CF per Share |
9.88 | 7.61 | 7.24 | 6.40 | |
Capex per Share |
(0.45) | (0.48) | (0.43) | (0.41) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 |
Columns are period end dates